logo
About
R&D
Pipeline
Investors
News
Contact
For Patients
Primary Sclerosing Cholangitis
Nonalcoholic Steatohepatitis (NASH)
(NASH) דלקת כבד על רקע שומני
Investor Relations
Investor Relations
Overview
News & Events
News
Events
Presentations
Contact IR
Email Alerts
Financials & Filings
SEC Filings
Annual Reports
Quarterly Results
Stock
Stock Quote & Chart
Historical Stock Price
Analyst Coverage
Corporate Governance
Board Committees
Board of Directors
Leadership
Documents
News
Events
Presentations
Contact IR
Email Alerts
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Email Alerts
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update
March 17, 2023
Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 06, 2023
Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis
February 21, 2023
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
January 03, 2023
Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis
December 21, 2022
Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy
November 30, 2022
Chemomab Announces Appointment of Matthew Frankel, MD, MBA as Chief Medical Officer
November 14, 2022
Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 11, 2022
Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19
November 09, 2022
Chemomab Presents Preclinical Data at AASLD The Liver Meeting® 2022 Highlighting Key Role of CCL24 in Pathophysiology of Primary Sclerosing Cholangitis
November 07, 2022
Load More
Loading...